Opinion: Pharmaceutical mergers and megamergers stifle innovation
Presidential candidates, lawmakers, policymakers, and the public should put pressure on regulators like the FTC to apply more scrutiny to multibillion-dollar mergers in the pharma industry.
It isn’t lost on the public that the pharmaceutical industry is putting profits over people. Over 80% of Americans across party lines believe that lowering drug costs should be a “top priority” for lawmakers. Policymakers across the political spectrum have put the industry on notice, holding hearings with pharmaceutical company CEOs and introducing a flurry of policies to rein in high-cost medicines.
President Trump also made lowering drug costs a priority, and went as far as accusing drugmakers of “getting away with murder” on the campaign trail.
Yet the industry continues to.
